Extracellular matrix protein turnover markers are associated with axial spondyloarthritis—a comparison with postpartum women and other non-axial spondyloarthritis controls with or without back pain

Port, Helena; Nielsen, Signe Holm; Madsen, Sofie Falkenløve; Bay-Jensen, Anne-Christine; Karsdal, Morten; Seven, Sengül; Sørensen, Inge Juul; Morsel-Carlsen, Lone; Østergaard, Mikkel; Pedersen, Susanne Juhl

doi:10.1186/s13075-022-02839-1

Table 5 Diagnostic value of biomarker levels for axSpA

From: Extracellular matrix protein turnover markers are associated with axial spondyloarthritis—a comparison with postpartum women and other non-axial spondyloarthritis controls with or without back pain

	AxSpA vs women with postpartum pain				AxSpA vs disc herniation patients				AxSpA vs healthy controls
	AUROC [95% CI]	T	S	SP	AUROC [95% CI]	T	S	SP	AUROC [95% CI]	T	S	SP
C1M	0.66 [0.50–0.82]	66.2	0.96	0.43	0.59 [0.40–0.78]	67.8	0.92	0.43	0.73 [0.61–0.86]	72.7	0.98	0.43
C2M	0.41 [0.24–0.58]	18.2	0.25	0.87	0.38 [0.18–0.58]	35.2	1.00	0.043	0.56 [0.42–0.70]	19.8	0.44	0.78
T2CM	0.60 [0.43–0.77]	5.4	0.71	0.61	0.51 [0.30–0.72]	5.6	0.75	0.48	0.56 [0.42–0.70]	5.4	0.65	0.61
C3M	0.50 [0.32–0.68]	18.1	1.00	0.26	0.45 [0.25–0.66]	15.9	0.75	0.35	0.54 [0.39–0.69]	20.1	0.98	0.22
C4M	0.65 [0.47–0.82]	33.9	0.92	0.57	0.57 [0.35–0.78]	28.1	0.67	0.61	0.68 [0.54–0.82]	33.7	0.81	0.57
C6M	0.68 [0.51–0.84]	19.6	0.88	0.57	0.47 [0.27–0.68]	23.1	0.75	0.35	0.73 [0.59−0.87]	19.4	0.90	0.57
C10C	0.42 [0.25–0.59]	2924.8	0.88	0.22	0.49 [0.28–0.70]	1698.7	0.083	1.00	0.61 [0.47–0.75]	2332	0.54	0.70
COL10NC	0.45 [0.28–0.62]	13.7	0.96	0.22	0.50 [0.29–0.72]	13.5	0.92	0.22	0.36 [0.21–0.51]	16.4	0.96	0.13
PROM	0.75 [0.61−0.89]	0.27	0.83	0.65	0.59 [0.40–0.79]	0.34	0.92	0.43	0.69 [0.56−0.82]	0.34	0.91	0.43
VICM	0.77 [0.63−0.91]	3.6	0.79	0.70	0.68 [0.48–0.89]	2.6	0.58	0.83	0.72 [0.58−0.85]	3.0	0.59	0.78
CRPM	0.65 [0.49–0.81]	11.1	0.75	0.57	0.58 [0.37–0.80]	11.5	0.75	0.52	0.62 [0.47–0.77]	11.7	0.75	0.52
PRO-C2	0.43 [0.26–0.60]	21.6	0.50	0.57	0.54 [0.31–0.78]	16.7	0.42	0.91	0.47 [0.33–0.61]	16.7	0.15	0.91
PRO-C3	0.48 [0.31–0.65]	10.8	0.67	0.43	0.39 [0.20–0.58]	11.5	0.75	0.3	0.36 [0.21–0.50]	18.1	0.98	0.043
PRO-C4	0.75 [0.61−0.89]	7227	0.79	0.65	0.59 [0.39–0.80]	7575.1	0.83	0.43	0.82 [0.73−0.92]	7224.1	0.88	0.65
PRO-C6	0.39 [0.22–0.55]	10.1	0.92	0.13	0.45 [0.23–0.66]	12.5	1.00	0.087	0.60 [0.45–0.74]	5.1	0.31	0.91
C2M/PRO-C2	0.46 [0.28–0.63]	0.54	0.12	1.00	0.43 [0.20–0.66]	0.91	0.42	0.74	0.56 [0.41–0.70]	1.1	0.65	0.57
C3M/PRO-C3	0.53 [0.36–0.71]	2.2	1.00	0.22	0.49 [0.28–0.70]	2.3	1.00	0.22	0.61 [0.46–0.75]	1.2	0.48	0.74
C4M/PRO-C4	0.53 [0.35–0.72]	0.004	0.75	0.52	0.56 [0.36–0.77]	0.0052	0.92	0.35	0.53 [0.36–0.69]	0.005	0.85	0.39
C6M/PRO-C6	0.71 [0.56–0.86]	3.0	0.79	0.61	0.56 [0.35–0.77]	2.5	0.42	0.78	0.61 [0.47–0.76]	3.1	0.73	0.57
CRP	0.80 [0.67–0.93]	1.9	0.88	0.61	0.71 [0.54–0.88]	2.5	0.83	0.57	0.83 [0.73–0.93]	1.8	0.85	0.65

The analyses were performed using AUROC, and threshold, sensitivity and specificity are provided. AUC that had statistical significance of p < 0.001 are highlighted in bold
Abbreviations: AUROC area under receiver operator characteristics curve, T threshold (ng/ml), S sensitivity, SP specificity, CI confidence interval, C1M metalloproteinase (MMP)-degraded type I collagen, C2M metalloproteinase (MMP)-degraded type II collagen, T2CM MMP-1 and MMP-13-mediated degradation of type II collagen, C3M MMP-degraded type III collagen, C4M MMP-degraded type IV collagen, C6M MMP-degraded type VI collagen, C10C cathepsin-K-mediated degradation of type X collagen, COL10NC NC domain of type X collagen, PROM MMP-1 and MMP-13-mediated degradation of prolargin, VICM citrullinated and MMP-degraded vimentin, CRPM C-reactive protein metabolite, CRP C reactive protein, PRO-C2 pro-peptide of type II collagen, PRO-C3 pro-peptide of type III collagen, PRO-C4 pro-peptide of type IV collagen, PRO-C6 pro-peptide of type VI collagen

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us